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The tight regulation of sleep/wake states is critical for mental and physiological wellbeing.
For example, dysregulation of sleep/wake systems predisposes individuals to metabolic
disorders such as obesity and psychiatric problems, including depression. Contributing
to this understanding, the last decade has seen significant advances in our appreciation
of the complex interactions between brain systems that control the transition between
sleep and wake states. Pivotal to our increased understanding of this pathway was
the description of a group of neurons in the lateral hypothalamus (LH) that express
the neuropeptides orexin A and B (hypocretin, Hcrt-1 and Hcrt-2). Orexin neurons were
quickly placed at center stage with the demonstration that loss of normal orexin function
is associated with the development of narcolepsy—a condition in which sufferers fail
to maintain normal levels of daytime wakefulness. Since these initial seminal findings,
much progress has been made in our understanding of the physiology and function of the
orexin system. For example, the orexin system has been identified as a key modulator of
autonomic and neuroendocrine function, arousal, reward and attention. Notably, studies in
animals suggest that dysregulation of orexin function is associated with neuropsychiatric
states such as addiction and mood disorders including depression and anxiety. This review
discusses the progress associated with therapeutic attempts to restore orexin system
function and treat neuropsychiatric conditions such as addiction, depression and anxiety.
We also highlight potential pitfalls and challenges associated with targeting this system to
treat these neuropsychiatric states.
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OVERVIEW—THE OREXIN SYSTEM IN BRIEF
First described in 1996, the orexins are two neuropeptides
expressed by a few thousand neurons within the perifornical
area (PFA), the dorsomedial hypothalamus (DMH) and the lat-
eral hypothalamus (LH) (de Lecea et al., 1998; Sakurai et al.,
1998). The binding target of these ligands, termed orexin A
and B, are two G-protein coupled receptors OxR1 and OxR2
(de Lecea et al., 1998; Sakurai et al., 1998). Orexin A is non-
selective for both OxR1 and OxR2 whereas orexin B is more
selective for OxR2 (Sakurai et al., 1998; Ammoun et al., 2003).
A key feature of this relatively small population of neurons
is their widespread projections throughout the brain, includ-
ing other hypothalamic nuclei, the midline paraventricular tha-
lamus (PVT), brain stem nuclei and a number of structures
involved in reward behavior including the ventral tegmental
area (VTA) and nucleus accumbens shell (NACs) (Peyron et al.,
1998). In these projection areas, the expression of orexin recep-
tor subtypes is partially overlapping, however, some regions
preferentially express one receptor subtype, presumably pro-
viding some degree of selectivity (certainly in terms of poten-
tial pharmacological selectivity of different target regions). For
example, the prefrontal cortex predominantly expresses OxR1,
whereas the nucleus accumbens (NAC) mainly expresses OxR2
(Marcus et al., 2001).
Consistent with the widespread projections of these neurons,
orexins have been implicated in a number of physiological func-
tions, including regulation of sleep (Chemelli et al., 1999), energy
metabolism (Burdakov et al., 2005), arousal (Sutcliffe and de
Lecea, 2002; Taheri et al., 2002), behavioral and neuroendocrine
responses to stress (Ida et al., 2000; Furlong et al., 2009) and
reward-seeking behavior (Boutrel et al., 2005; Harris et al., 2005;
Lawrence et al., 2006; Marchant et al., 2012). The role of orexin
in this diverse range of functions has been reviewed extensively
elsewhere (Boutrel and de Lecea, 2008; Aston-Jones et al., 2010;
Boutrel et al., 2010; Lawrence, 2010; James et al., 2012; Mahler
et al., 2012). In this review, we will highlight new research
focused on changes in the intra-hypothalamic LH-orexin cir-
cuitry induced by drugs of abuse and stress. We will also outline
recent data highlighting the clinical potential of single and dual
orexin receptor antagonists (SORAs and DORAs) for neuropsy-
chiatric conditions including addiction, anxiety and depression.
However, we also discuss recent findings indicating that several
challenges must be overcome for the therapeutic value of SORAs
and DORAs to be fully realized.
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CELLULAR AND MOLECULAR EVIDENCE FOR TARGETING
THE LH-OREXIN SYSTEM IN DRUG ADDICTION
Until recently, work on the relationship between the orexin system
and addiction has been heavily focused on the antagonism of
orexin actions in downstream projection areas (James et al., 2011;
Brown et al., 2013; Mahler et al., 2013). At the same time, the
issue of how drugs of addiction might alter the properties of
orexin neurons has been largely overlooked. Interestingly, gene
expression analysis has shown that the LH is highly transcription-
ally responsive to addictive drugs (Ahmed et al., 2005). Ahmed
et al. (2005) found that rats given extended access to cocaine
displayed a profound increase in both pre- and post-synaptic
markers of plasticity in the LH. Further, studies from the feed-
ing literature suggest that excitatory inputs onto orexin neurons
can undergo significant rewiring in response to food-deprivation
and re-feeding. These results suggest that the LH orexin cir-
cuitry is likely to undergo experience-dependent neuroplasticity
in response to cocaine treatment.
Given the above evidence, our group has undertaken a series
of studies to assess how drugs might remodel LH orexin circuits.
In these experiments, rats were exposed to 7 days of cocaine injec-
tions or allowed to self-administer cocaine for 14 days before exci-
tatory synaptic transmission was assessed in LH slices. This work
showed that both experimenter- and self-administered cocaine
significantly increased excitatory drive in the LH through pre-
synaptic mechanisms, assessed using mEPSCs frequency, ampli-
tude and paired pulse ratio (Yeoh et al., 2012). Consistent with
our electrophysiological findings, the number of putative exci-
tatory but not inhibitory inputs onto PFA/LH cells were signif-
icantly increased, as measured by immunolabeling for vesicular
glutamate transporter 2 (VGLUT2) or vesicular GABA trans-
porter (VGAT; Yeoh et al., 2012). Importantly, a population of
recorded neurons that were recovered with neurobiotin labeling
and immunolabeled for orexin confirmed that these increases in
excitatory drive occurred in orexin neurons.
Somewhat surprisingly, a recent study by a different group
failed to find evidence of pre-synaptic plasticity in orexin neurons
after 3 days of cocaine exposure (Rao et al., 2013). However, this
regimen of cocaine exposure did promote long-term potentiation
(LTP) at glutamate synapses onto orexin neurons, which persisted
for more than 5 days post-withdrawal (Rao et al., 2013). The dif-
ferences in the Rao et al. (2013) study and our ownmay in part be
explained by differences in experimental procedures. In our study,
we carried out both intraperitoneal (i.p) injections and cocaine
self-administration in rats as compared to the Rao study, which
employed a conditioned place preference (CPP) model whereby
mice received only experimenter-administered cocaine injections.
Animals that underwent i.p injections in our study received a
slightly higher dose of cocaine for a longer period of time as
compared to Rao and colleagues (15mg/kg/7 days vs. 10mg/kg/3
days). Further, our animals which were trained to self-administer
cocaine (14 days, 0.25mg/0.1ml/infusion) did not show signs
of post-synaptic adaptations. Therefore, species differences are
unlikely to have contributed to this disparity. Furthermore, pre-
liminary experiments in our laboratory indicate similar pre-
synaptic effects in mice. A more likely explanation might be that
in our study, all experimental procedures were carried out during
the active (dark) phase while CPP procedures performed by Rao
et al. (2013) occurred during the inactive (light) phase. Despite
these differences in experimental procedures, both experiments
indicate that cocaine induces synaptic plasticity in LH orexin cir-
cuitry (Figures 1A, B). These data, which indicate that addiction
leads to an overstimulation of orexin neurons, may provide a
mechanistic rationale for antagonizing the downstream actions of
enhanced orexin signaling in addiction using SORAs and DORAs.
Furthermore, evidence exists that altered feeding behav-
ior modifies LH orexin neuron circuitry at a cellular level.
Specifically, work using an orexin-GFP mouse to selectively study
the properties of orexin neurons showed an increase in minia-
ture excitatory post-synaptic currents (mEPSCS), a measure of
increased synaptic drive, in LH slices of mice that underwent mild
food restriction for 24 h, as compared to normally-fed controls.
Consistent with these electrophysiological findings, and simi-
lar to our LH addiction experiments, overnight food restriction
promoted the formation of excitatory VGLUT2 synapses onto
orexin neurons. These cellular effects of food restriction were
rapidly reversed by re-feeding (Horvath and Gao, 2005), contrast-
ing the addiction work where comparable cellular perturbations
persisted beyond the removal of drug. Together, these behavioral
and cellular studies highlight the potential impact for SORAs and
DORAs on appetite and natural rewards.
Importantly, the source of the enhanced excitatory drive to
orexin neurons remains to be determined. The LH receives sig-
nificant glutamatergic inputs from other brain regions such as
the prefrontal cortex, lateral septum and basolateral amygdala.
For example, Morshedi and Meredith (2008) have shown that a
sensitizing regimen of amphetamine upregulates Fos immunore-
activity in medial prefrontal cortex neurons projecting to the LH.
Further, cocaine CPP has also been demonstrated to produce
increased Fos immunoreactivity in the lateral septum, another
area that projects to the LH (Sartor and Aston-Jones, 2012).
It is also worth noting the possibility that local glutamatergic
neurons may provide positive feedback to the orexin system in
cocaine-exposed animals (Li et al., 2002; Jennings et al., 2013).
Nonetheless, further studies are needed to confirm the likely
source of these increased glutamatergic inputs onto orexin neu-
rons in response to cocaine exposure and to determine how other
classes of drugs might also rewire LH-orexin circuits. A final point
that should be noted is that recent elegant work by Burdakov’s
group has demonstrated the existence of two subpopulations of
orexin neurons in the LH (termedH-type and D-type), which can
be distinguished electrophysiologically and anatomically (Schöne
et al., 2011). It will be important for future studies to determine
if drugs of abuse (or stress) differentially affect these orexin cell
subtypes.
EFFECTS OF SORAs AND DORAs ON DRUG-SEEKING
BEHAVIORS
A number of SORAs now exist, the most common being those
that target the OxR1. These include SB-334867 (Porter et al.,
2001; Smart et al., 2001), SB-674042 (Langmead et al., 2004), SB-
408124 (Langmead et al., 2004), SB-410220 (Porter et al., 2001;
Langmead et al., 2004), GSK1059865 (Gozzi et al., 2011) and,
most recently, ACT-335827 (Steiner et al., 2013a) all of which have
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FIGURE 1 | The effect of cocaine and stress exposure on orexin neurons.
(A) Under basal conditions, orexin (Orx) neurons in the lateral hypothalamus
receive excitatory inputs, thus providing “normal” glutamatergic and
orexinergic (excitatory) tone onto downstream projection targets such as
ventral tegmental area (VTA) dopamine (DA) neurons. (B) Based on recent
studies, we propose that chronic cocaine-exposure rewires glutamatergic
inputs onto Orx neurons resulting in increased excitatory drive onto DA
neurons in the VTA. (C) Anxiety and acute stress are able to cause
enhanced excitatory drive to DA neurons in the VTA and Noradrenergic (NA)
neurons in the Locus Coeruleus (LC), an important projection target of
orexin neurons. (D) Glutamatergic inputs onto Orx neurons in chronically
stressed animals are impaired resulting in reduced excitatory drive onto DA
and/or NA neurons. On the basis of this simplified hypothetical mechanistic
rationale, orexin receptor antagonism represents a possible therapeutic
intervention to treat anxiety and addictions. In the case of reduced orexin
system activity, as may occur in some forms of depression or in response to
chronic stress, mechanisms to augment orexin function may be required.
Whether chronic modulation of these systems can be achieved without
precipitating the expression of an alternate neuropsychiatric state warrants
careful consideration.
at least 50-fold selectivity for OxR1 over OxR2 (Scammell and
Winrow, 2011; Zhou et al., 2011). Amongst these compounds,
SB-334867 has been most widely studied in terms of behavioral
pharmacology, largely due to the high selectivity, potency and
availability of this drug (Scammell andWinrow, 2011; Zhou et al.,
2011).
A large number of studies have demonstrated that OxR1
antagonists are effective at blocking addiction-related behaviors
across a range of drug classes. With respect to self-administration
behavior, treatment with SB-334867 effectively attenuates ethanol
and nicotine self-administration under both low-effort fixed
ratio (FR) and higher-effort progressive ratio (PR) schedules
(Lawrence et al., 2006; Schneider et al., 2007; Hollander et al.,
2008; LeSage et al., 2010; Jupp et al., 2011; Martin-Fardon and
Weiss, 2012). Interestingly, in the case of cocaine, SB-334867
has no effect on self-administration behavior under FR1 or
FR3 conditions (Smith et al., 2009; Espana et al., 2010) but
does attenuate self-administration under higher-effort schedules,
including FR5 (Hollander et al., 2012) and PR (Borgland et al.,
2009; Espana et al., 2010). These findings imply that in general,
the orexin system has limited actions on the primary reward-
ing effects of cocaine, but is important to overcome increased
motivational demands or effort to procure rewards. In con-
trast, SB-334867 effectively blocks the expression of CPP for
amphetamine (Hutcheson et al., 2011) and morphine (Sharf
et al., 2010), a widely used measure of the rewarding effects of
drugs of abuse. Systemic SB-334867 treatment also attenuates
reinstatement of cocaine-seeking behavior elicited by drug cues
(Smith et al., 2009), contexts (Smith et al., 2010) and footshock
stress (Boutrel et al., 2005), but not a cocaine prime (Mahler
et al., 2013). Similarly, SB-334867 attenuates cue- and stress-
induced reinstatement of alcohol seeking (Lawrence et al., 2006;
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Richards et al., 2008; Jupp et al., 2011) as well as cue-induced,
but not primed, heroin seeking (Smith and Aston-Jones, 2012).
SB-334867 also attenuates cue- (Plaza-Zabala et al., 2013), but
not footshock- (Plaza-Zabala et al., 2010) induced reinstatement
of nicotine seeking—the latter result being a particularly sur-
prising outcome. Thus, a wealth of preclinical studies support
the premise that the use of OxR1 SORAs have the potential to
decrease addiction-related behaviors, suggesting they may have
clinical value in preventing relapse in abstinent patients.
In contrast to OxR1 antagonists, fewer studies have assessed
the effects of selective OxR2 antagonists on addiction-related
behaviors. This is likely due to the more recent development
of these compounds and a predicted increase in the likeli-
hood of sedation (Zhou et al., 2011). Selective OxR2 antago-
nists include JNJ-10397049 (McAtee et al., 2004; Dugovic et al.,
2009), EMPA (Malherbe et al., 2009a), and TCS-OX2-29 (Hirose
et al., 2003), all of which have at least a 250-fold selectivity for
OxR2 (Scammell and Winrow, 2011; Zhou et al., 2011). Studies
exploring the effects of these OxR2 SORAs have reported less
consistent effects on drug-motivated behaviors compared to the
OxR1 SORA SB-334867. For example, Shoblock et al. (2010)
showed that JNJ-10397049 dose-dependently deceased ethanol
self-administration, as well as the acquisition, expression and
reinstatement of ethanol CPP. In contrast, Brown et al. (2013)
showed that TCS-OX2-29 attenuated ethanol self-administration
but had no effect on cue-induced reinstatement of extinguished
ethanol seeking. Interestingly, these authors identified the nucleus
accumbens core (NACc) as an important site for OxR2 signal-
ing, as infusions of TCS-OX2-29 into the NACc, but not shell,
reduced ethanol self-administration. In contrast, OxR2 SORAs
have been shown to have no effect on cocaine self-administration
or reinstatement (Smith et al., 2009) or the expression of nico-
tine withdrawal symptoms (Plaza-Zabala et al., 2012). Thus,
regarding SORAs, the case for OxR1-based therapies in treat-
ing addiction is better developed than for antagonists targeting
OxR2.
With respect to DORAs, a large number of these compounds
have been developed, prompted largely by their potential as a
novel treatment for insomnia. Indeed, at least three pharmaceu-
tical companies (GSK, MERCK, Actelion) have initiated clinical
trials investigating the utility of DORAs in modulating the sleep-
wake cycle. These DORAs include almorexant (ACT-078573;
Brisbare-Roch et al., 2007; Malherbe et al., 2009b); suvorexant
(MK-4305; Cox et al., 2010), Merck DORA-1 (Bergman et al.,
2008), Merck DORA-5 (Whitman et al., 2009), and SB-649868
(Renzulli et al., 2011). Only a limited number of studies have
examined the effects of DORAs on addiction-related behav-
iors, with this work focusing almost exclusively on almorex-
ant. For example, systemic and intra-VTA almorexant treatment
was shown to attenuate ethanol self-administration (Srinivasan
et al., 2012). Similarly, systemic almorexant blocked nicotine self-
administration behavior (LeSage et al., 2010). Interestingly, whilst
almorexant attenuated the expression of CPP to high doses of
cocaine and amphetamine, it had no effect on morphine CPP
(Steiner et al., 2013c). This study also showed that almorexant
reduced the expression of behavioral sensitization to morphine
but not to cocaine or amphetamine (Steiner et al., 2013c).
EFFECT OF SORAs AND DORAs ON FOOD AND NATURAL
REWARD-SEEKING BEHAVIOR
An important consideration with respect to the potential clin-
ical application of orexin receptor antagonists is the effect of
these compounds on other appetitive behaviors, including food
seeking. Indeed, studies carried out immediately following the
discovery of the orexin peptides firmly implicated orexin in feed-
ing behavior, with intracerebroventricular (i.c.v.) infusions of
orexin shown to increase food consumption (Sakurai et al., 1998)
whereas systemic treatment with SB-334867 was found to block
feeding behavior (Haynes et al., 2000).
Since these initial demonstrations, subsequent studies have
sought to investigate whether doses of orexin receptor antagonists
that are required to block drug seeking also affect feeding behav-
ior. For example, Martin-Fardon and colleagues recently showed
that systemic administration of SB-334867 (1–10mg/kg, i.p)
attenuated reinstatement of cocaine seeking, but not sweetened-
condensed milk seeking, elicited by discriminative cues (Martin-
Fardon and Weiss, 2014). Similarly, Jupp et al. (2011) showed
that systemic injections of SB-334867 (5mg/kg) were sufficient
to reduce responding for both ethanol and sucrose under an
FR3 schedule of reinforcement. However, SB-334867 (5mg/kg)
attenuated responding for ethanol but not sucrose under a PR
schedule. The authors suggested that the contribution of orexin A
tomotivation for alcohol is independent of non-specific effects on
appetitive drive. Likewise, Hollander et al. (2012) showed that sys-
temic injections of SB-334867 (2–4mg/kg) reduced cocaine self-
administration, but had no effect on responding for food rewards
under an FR5 schedule. Comparable effects have also been shown
with doses of SB-334867 that attenuate responding for nicotine
(LeSage et al., 2010). Further, we have previously reported that
intra-VTA infusions of SB-334867, at doses that suppress cue-
induced cocaine seeking, had no effect on reinstatement for a nat-
ural reward (sweetened condensed milk; James et al., 2012). With
respect to OxR2 antagonists, Brown et al. (2013) showed that cen-
tral infusions of 100µg TCS-OX2-29 reduced self-administration
of ethanol, but had no effect on sucrose self-administration. In
contrast however, LeSage et al. (2010) showed that systemic treat-
ment with the DORA almorexant attenuated responding for both
food pellets and nicotine. Similarly, systemic almorexant sup-
pressed ethanol self-administration, and responding for sucrose
(Srinivasan et al., 2012).
Taken together, these data indicate that a putative thera-
peutic window exists in which SORAs could be used to treat
addiction-relevant behaviors, including ‘relapse,’ without pro-
ducing ‘off-target’ effects on natural reward-seeking behavior.
Conversely, it appears likely that the use of DORAs in the treat-
ment of addiction may be associated with a risk of interfering
with natural appetitive processes or promoting sedation. It is also
important to acknowledge that there are very few studies that have
assessed the effect of subchronic or chronic orexin receptor antag-
onism on drug or food-motivated behavior (discussed below).
RECENT PROGRESS IMPLICATING THE OREXIN SYSTEM IN
STRESS-RELATED NEUROENDOCRINE RESPONSES
Activation of the hypothalamic-pituitary-adrenal (HPA) axis is an
important component of the adaptive response to stress (Dayas
Frontiers in Neuroscience | Neuropharmacology February 2014 | Volume 8 | Article 36 | 4
Yeoh et al. Orexin antagonists for neuropsychiatric disease
et al., 2001; Day andWalker, 2007; Ulrich-Lai andHerman, 2009).
In this regard it is noteworthy that the neuroendocrine paraven-
tricular nucleus (PVN), the apex of the HPA axis, contains both
OxR1 andOxR2 and that both receptor sub-types are expressed in
the anterior and intermediate lobe of the pituitary gland (Trivedi
et al., 1998; Date et al., 2000). Consistent with this anatomical evi-
dence, several reports have suggested that orexins can modulate
the HPA axis. For example, i.c.v. injections of orexin have been
shown to increase Fos-protein expression in PVN corticotropin-
releasing factor (CRF) neurons (Sakamoto et al., 2004), provoke
adrenocorticotropin-releasing hormone (ACTH) release from the
anterior pituitary, and increase the release of corticosterone from
the adrenal glands (Jászberényi et al., 2000; Kuru et al., 2000;
Russell et al., 2001; Moreno et al., 2005).
Importantly, researchers using systemic administration of
orexin receptor antagonists have reported less consistent effects
on HPA axis activity as would have been predicted from stud-
ies assessing HPA axis activity after orexin peptide infusions.
For example, systemic injections of the OxR1 antagonist GSK-
1059865 did not alter corticosterone responses to the pharma-
cological stressor yohimbine in rats (Gozzi et al., 2011, 2013).
Further, oral treatment with almorexant had no effect on basal,
social interaction, novelty or restraint stress-induced corticos-
terone release (Steiner et al., 2013b). Systemic SB-334867 admin-
istration also did not attenuate withdrawal-induced increases in
plasma corticosterone release (Laorden et al., 2012) despite reduc-
ing the physical symptoms associated with morphine withdrawal
in Wistar rats.
These equivocal effects of orexin on HPA axis function are
somewhat surprising given the abundance of orexin receptors
in the PVN and pituitary (Trivedi et al., 1998). Interestingly,
i.c.v. administration of TCS-OX2-29, a selective OxR2 antagonist,
attenuated swim stress-induced increases in plasma ACTH release
(Chang et al., 2007) and, intra-PVT infusions of SB-334867 atten-
uated the ACTH response to restraint but only following repeated
swim stress (Heydendael et al., 2011). Thus, any role of orexin in
HPA axis control might depend on prior stress exposure, the cat-
egory of stressor e.g., physical vs. psychological, its intensity and
duration, or whether in repeated stress experiments, homotypic
or heterotypic stressors are applied.
Despite the above data, exposure to psychological and physi-
cal stressors increase surrogate indices of orexin system function.
For example, increased Fos-protein expression is observed in
orexin neurons following exposure to acute footshock (Harris and
Aston-Jones, 2006), fear-associated contexts and novel environ-
ments (Furlong et al., 2009). Interestingly, similar effects are not
observed following acute immobilization stress (Furlong et al.,
2009), however this form of stress does increase orexin mRNA
levels in the LH (Ida et al., 2000). An explanation for these
contrasting findings remains to be determined, however, one
interpretation is that only sufficiently intense or salient stimuli
recruit the orexin system and that prior arousal state strongly
influences the likelihood of orexin system recruitment. With
respect to pharmacological stressors, increased Fos-expression
is observed in orexin neurons following systemic injections of
the anxiogenic drug FG-7142 (Johnson et al., 2012), caffeine
(Johnson et al., 2012) and intravenous administration of sodium
lactate (Johnson et al., 2010). Additionally, systemic administra-
tion of OxR1 antagonist GSK-1059865 has demonstrated func-
tional inhibition in stress-relevant brain regions such as the NAC,
dorsal thalamus, amygdala, and ventral hippocampus following
the administration of yohimbine (Gozzi et al., 2013).
Acute stress also appears to have long lasting effects on orexin
gene expression. For example, 2 weeks following a single session
of footshock stress, increased prepro-orexin mRNA levels were
observed in both the medial and lateral divisions of the hypotha-
lamus (Chen et al., 2013). Elevated levels of orexin-A peptide
in the cerebrospinal fluid (CSF) of Wistar rats have also been
demonstrated following a short-term forced swimming paradigm
(Martins et al., 2004). In addition, increased orexin mRNA was
observed in rats immediately following morphine withdrawal
(Zhou et al., 2006). Consistent with this Fos-activity mapping
of orexin cell reactivity to stress, acute orexin peptide infusions
evoke anxiety-like behavior. Specifically, i.c.v. administration of
orexin-A produced anxiogenic-like effects i.e., increased the time
spent in the closed arms of the elevated plus maze and the time
spent in the dark compartment of the light-dark test (Suzuki et al.,
2005). Orexins have also been shown to modulate the activity of
extrahypothalamic CRF systems with i.c.v. injections of orexin-A
found to increase the percentage of CRF cells that express Fos in
the central amygdaloid nucleus (Sakamoto et al., 2004). Together,
this evidence forms the basis for the hypothesis that manipula-
tion of the orexin system using SORAs and DORAs will likely also
impact on stress–induced anxiety-like behavior.
EFFECT OF SORAs AND DORAs ON ACUTE BEHAVIORAL
STRESS REACTIVITY AND ANXIETY-LIKE BEHAVIOR
Several recent preclinical studies indicate that SORAs and DORAs
have a limited effect on basal/non-stress evoked behavioral
responses including anxiety-like behavior. For example, systemic
treatment with SB-334867 in both rats and mice had no effect
on activity in the elevated plus maze and social interaction task,
two common tests of anxiety-like behavior (Johnson et al., 2010;
Rodgers et al., 2013). However, intra-PVT SB-334867 infusions
resulted in decreased anxiety-like behavior in the elevated plus
maze (Heydendael et al., 2011). This could indicate an important
role for orexin signaling in the PVT in regulating basal arousal or
anxiety state.
Importantly, SORAs reliably attenuated anxiety-like behavior
evoked by an acute psychological or physical stressor. For exam-
ple, systemic SB-334867 administration reduced the expression
of anxiety-like behavior induced by acute nicotine (Plaza-Zabala
et al., 2010) and sodium lactate injections (Johnson et al., 2010)
as well as cat odor (Staples and Cornish, 2014). Administration
of SORAs also reduced physiological responses such as increased
heart rate and body temperature produced by exposure to acute
i.p injection stress (Rusyniak et al., 2012). With regards to OxR2
antagonists, intra-PVT infusions of TCS-OX2-29 reduce anxiety-
like behavior elicited by footshock stress (Li et al., 2010) suggest-
ing a role for orexin signaling through the OxR2 in stress-relevant
behaviors.
There are also several recent animal studies that have explored
the role for the orexin system in anxiety-like behavioral responses
to conditioned cues that predict the presentation of a fearful
www.frontiersin.org February 2014 | Volume 8 | Article 36 | 5
Yeoh et al. Orexin antagonists for neuropsychiatric disease
stimulus, such as footshock. This approach has been used to
explore brain mechanisms responsible for generating panic dis-
order and post-traumatic stress disorder in humans (Grillon,
2008). In male Sprague-Dawley rats, Sears et al. (2013) adminis-
tered SB-334867 i.c.v. before fear conditioning and demonstrated
an impairment in conditioned stimulus (CS)-induced freezing
behavior 24 h after CS/unconditioned stimulus (US) presenta-
tion. Further, systemic injections of TCS-1102 decreased condi-
tioned and generalized fear and anxiety-like behavior in an open
field in rats previously exposed to footshock stress (Chen et al.,
2013). Moreover, OxR1 knockout mice demonstrated a reduction
in freezing behavior in both cued and contextual fear condi-
tioning. Interestingly, OxR2 knockout mice also showed reduced
freezing behavior to contextual but not conditioned fear (Soya
et al., 2013). Consistent with a role for both receptor subtypes
in aspects of conditioned fear responses, Steiner et al. (2012)
reported that oral administration of almorexant reduced fear-
potentiated startle in response to a CS but found no change in
elevated plus maze behavior. Interestingly, human genetic studies
have linked a polymorphism in Orx-2 receptor gene with panic
disorder (Annerbrink et al., 2011).
Together these data indicate that exposure to acute stress and
the expression of anxiety-like behavior is generally associated with
increases in orexin system activity. Further, orexin antagonists
appear to be potential candidates for the suppression of anxiety-
like behavior and maladaptive stress-reactivity. Importantly, as is
outlined below, recent evidence suggests that chronic suppres-
sion of the orexin systemmay be associated with the development
of depression-like symptomology. These findings have significant
implications for the potential use of orexin antagonists in the
treatment of neuropsychiatric disorders.
EFFECT OF CHRONIC STRESS ON THE OREXIN SYSTEM AND
IMPLICATIONS FOR DEPRESSION
In recent human studies, a polymorphism in Orx-1 receptor gene
has been associated with major mood disorders and increased
orexin peptide levels were correlated with positive emotions and
social interaction (Rainero et al., 2011; Blouin et al., 2013).
Non-genetic factors, such as chronic stress, have also implicated
orexin in the etiology of depression (Katz et al., 1981; Kendler
et al., 1999; Charney and Manji, 2004; Russo and Nestler, 2013).
This link has been studied in animal models typically involv-
ing extended periods of psychological stress exposure (Lutter
et al., 2008). Increasing evidence from these types of studies
links chronic stress exposure to a downregulation of orexin sys-
tem activity. For example, mice exposed to the well characterized
social defeat model of chronic stress, which evokes symptoms
thought to mimic depression in humans, display reduced orexin
mRNA expression, lowered orexin cell number, and diminished
levels of orexin A and orexin B peptide (Lutter et al., 2008; Nocjar
et al., 2012). Similarly, Wistar-Kyoto (WKY) rats, which exhibit
a depressive-like behavioral phenotype, express lower numbers
of orexin neurons and a smaller orexin soma size compared to
Wistar rats (Allard et al., 2004). The WKY rat strain also exhibits
reduced prepro-orexin mRNA levels and orexin A immunore-
activity is reduced in the hypothalamus, thalamus, septum and
amygdala (Taheri et al., 2001).
Early life stress (ELS) is a known risk factor for the devel-
opment of stress-related mood disorders in adulthood (Graham
et al., 1999). Surprisingly though, work has shown that ELS in fact
increases frontal cortical OxR1 and hypothalamic orexin A levels
in adulthood (Feng et al., 2007). Given these results, we recently
investigated the effects of ELS on the reactivity of the orexin sys-
tem to a second psychological stressor in adulthood. Both male
and female rats exposed to neonatal maternal separation dis-
played a hypo-active orexin cell response to stress in adulthood.
These animals also displayed reduced open field behavior but
notably no overt anxiety-like behavior was observed on an ele-
vated plus maze. Our interpretation of these data is that the ELS
procedures evoked behaviors more akin to a depression-like pro-
file after stress however further behavioral tests will be necessary
to further explore this hypothesis (Campbell et al., 2013).
What effect a second stressor, such as restraint in adulthood,
might have on LH-orexin circuits is unknown. This would seem
important given the behavioral effects of this “two-hit” paradigm
outlined above (Campbell et al., 2013). It is possible that increased
drive to this system reflects an attempt to enhance orexin activity
and prevent the expression of depression-like behavior. It may be
that in response to a significant subsequent stressor, the reduced
functional integrity at a synaptic andmolecular level is unmasked,
which may then develop into a depressive-like state. Regardless,
taken together with the Fos data outlined above, our findings
suggest that ELS can have long-term impacts on the normal
functioning of orexin cells.
Consistent with a process where ELS can induce orexin
cell dysfunction and depression-like behaviors, clinical evidence
supports the possibility that decreased orexin signaling might
promote depression-like behaviors. For example, reduced con-
centrations of orexin A were reported from CSF samples of adults
with major depressive disorder and chronic, combat-related post-
traumatic stress disorder (Brundin et al., 2007a,b, 2009; Strawn
et al., 2010). Additionally, reduced orexin A mRNA has been
correlated with increased scores on the Hamilton rating scale
for depression (Rotter et al., 2011). Interestingly, infusions of
orexin peptides into the ventricles of rats have been shown to
have antidepressant-like effects. For example, i.c.v. administra-
tion of orexin reduces the duration of immobility in the forced
swim test, and this effect is blocked by the administration of the
OxR1 antagonist, SB-334867 (Ito et al., 2008). Thus, it is possible
that in some forms of depression, increasing orexin system signal-
ing may have therapeutic benefit. In line with this interpretation,
we recently found that a period of exercise in adolescence pre-
vented reductions in orexin system function and the expression
of stress-related behavior in rats exposed to ELS (Campbell et al.,
2013).
Despite the above work, it is important to acknowledge that
there are both preclinical animal and human data that do not
support a link between a hypoactive orexin system and depres-
sion. For example, Mikrouli et al. (2011) demonstrated that the
Flinders Sensitive Line, considered a genetic rat model of depres-
sion, displayed elevated, not depressed, levels of orexin neurons
compared to controls. Further, Nollet et al. (2011) demonstrated
that mice subjected to unpredictable chronic mild stress displayed
increased depressive-like behavior following the tail suspension
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test but presented with elevated orexin neuron activity in the
DMH and PFA subregions of the hypothalamus. Interestingly,
these authors were able to reverse this elevation in orexin cell
activity with 6 weeks of fluoxetine treatment. Similarly, expo-
sure to unpredictable chronic mild stress produced depressive-
like behaviors in the tail suspension test, elevated plus maze
and resident-intruder task; and 7 weeks exposure to the DORA
almorexant produced an antidepressant-like behavioral effect in
these tasks (Nollet et al., 2012). And, in a recent study, OxR1
mRNA expression in the amygdala was reported to be positively
correlated with increased depressive-like behavior in the forced
swim test (Arendt et al., 2013) - however it is possible that this
effect might be caused by downregulated orexin system function.
Finally, a recent study reported that decreased depressive-like
behavior is observed in OxR1 knockout mice, whereas OxR2
knockout mice exhibit increased depressive-related behavior, pos-
sibly pointing to a differential role for OxR1 vs. OxR2 in the
regulation of these behaviors (Scott et al., 2011). These authors
highlight the fact that behavioral pharmacology studies typically
use the non-selective OxR agonist orexin-A, along with SORAs at
doses that are potentially non-selective in vivo, thereforemaking it
difficult to differentiate roles for OxR1 vs. OxR2 in the regulation
of depression-like behavior.
In human studies, Salomon et al. (2003) reported that orexin A
CSF levels were higher in depressed patients and treatment with
sertraline, an antidepressant drug, resulted in an attenuation of
CSF orexin levels. Furthermore, a positive correlation between
orexin plasma concentrations, depressive symptoms and global
distress indices on the brief symptom inventory is seen following
alcohol withdrawal (von der Goltz et al., 2011). Finally, Schmidt
et al. (2011) failed to find any association between CSF orexin A
levels and depression.
Taken together, these results suggest that acute stress may acti-
vate the orexin system in order to enhance an animal’s ability to
cope or adapt appropriately to a potential threat (Figure 1C). If
these stressors persist, chronic or repeated exposure to stress may
downregulate orexin system function (Figure 1D). Hypoactivity
of the orexin system may impair an animal’s ability to adapt
to stress and lead to the expression of depressive-like behav-
ior. Data from human and animal studies not supporting this
link may reflect the heterogeneous nature of depression—i.e.,
depression presenting with and without anxiety or anxiety pre-
senting with or without depression. Supporting this conclusion,
Johnson et al. (2010) found that patients exhibiting panic anx-
iety displayed increased CSF orexin levels compared to patients
exhibiting panic anxiety with comorbid major depressive disor-
der. It will be important for human and animal studies exploring
the link between the orexin system dysfunction and neuropsy-
chiatric conditions to consider the heterogeneous nature of these
conditions.
POTENTIAL PITFALLS FOR APPROACHES TO TREAT
NEUROPSYCHIATRIC DISORDERS USING OREXIN RECEPTOR
ANTAGONISTS
As outlined above, significant progress has been made in our
understanding of the contribution of the orexin system to nor-
mal and “pathological” behavior. In the case of addiction, there
seems sufficient evidence to conclude that the orexin system is
important for drug-seeking behavior, particularly for relapse-
like behavior provoked by drug-cues and stress but not by drug
itself. Further, several studies indicate that orexin antagonists,
and in particular selective OxR1 antagonists, can reduce drug-
seeking at doses that have minimal effects on natural reward-
seeking behavior (Jupp et al., 2011; Hollander et al., 2012; James
et al., 2012; Brown et al., 2013). Comparison of orexin’s role
in drug taking vs. seeking behavior also highlights that orexin
receptor antagonists have effects on rewarded self-administration,
but importantly these effects generally emerge only under high
effort schedules of reinforcement. These data combine to pro-
duce a compelling case that orexin receptors represent promis-
ing targets for the treatment of addiction. This is particularly
true given the long-established interaction between addiction
and maladaptation of natural reward seeking brain pathways.
For example, increased excitatory drive to the orexin system
is thought to heighten orexin signaling in key reward-seeking
regions such as the VTA and may contribute to the persis-
tent plasticity within dopamine neurons seen after long-term
cocaine self-administration and increased relapse vulnerability
(Chen et al., 2008; James et al., 2012)
It is important given the clinical promise of SORAs and
DORAs for neuropsychiatric disorders that studies continue to
assess the potential for off-target effects, tolerance to prolonged
orexin receptor blockade and differential or counter-regulatory
effects on OxR1 vs. 2, as well as any possible compensatory
adaptations that may occur in other hypothalamic neuropeptide
systems in response to chronic orexin receptor blockade. Studies
to date indicate a limited profile of chronic SORA and DORA
tolerance. For example, Steiner et al. (2013c) showed that 12
days of chronic almorexant treatment had no effect on the main-
tenance of CPP or locomotor sensitization in animals exposed
to cocaine, morphine or amphetamine. However, as mentioned
above, Nollet et al. (2012) exposed mice to chronic almorex-
ant treatment (7 weeks), which produced an antidepressant-like
effect in the tail suspension test, elevated plus maze and resident-
intruder task following exposure to unpredictable chronic mild
stress. Interestingly, chronic treatment with the OxR1 antagonist
ACT-335827 (4 weeks) did not alter total energy intake in cafe-
teria diet fed rats compared to controls (Steiner et al., 2013b). In
contrast, chronic SB-334867 treatment (14 days) had anti-obesity
effects in a model of genetically obese mice by reducing food
intake and body weight gain over the 14 day period (Haynes et al.,
2002).
In one of the few examples where repeated doses of an orexin
antagonist have been studied for addiction and relapse preven-
tion, Zhou and colleagues demonstrated that chronic SB-334867
exposure resulted in a complex pattern of effects (Zhou et al.,
2011). Specifically, they found that repeated SB-334867 expo-
sure prior to extinction sessions resulted in reduced cocaine-
seeking behavior in rats during extinction; however, repeated
SB-334867 treatment during extinction increased cue-induced
reinstatement and had no effect on cocaine-primed reinstate-
ment. Importantly, McNally and colleagues have also shown
that cocaine and alcohol-seeking do not necessarily evoke a spe-
cific drug context-related activation of the orexin system, rather,
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recruitment of this pathway is necessary but not sufficient for
drug-seeking behavior (Hamlin et al., 2007, 2008). It is also inter-
esting to note that the OxR1 antagonist, SB-334867, has been
shown to reduce cue-induced reinstatement of cocaine seek-
ing behavior in male rodents yet no effect was seen in female
rats (Zhou et al., 2012). Future work should focus on differ-
entiating arousal vs. reward related function of the orexin neu-
rons in the context of addiction. Sex-specific effects of stress
and drug exposure on orexin circuitry also warrant further
scrutiny.
With respect to the potential use of orexin receptor antago-
nists for anxiety and depression, recently, Johnson et al. (2010,
2012) proposed the use of OxR1 antagonists in the treatment of
panic disorder. Certainly, the available data appears to support
an important role for orexin signaling in ameliorating anxiety-
like states in animal models. Studies employing chronic stress
paradigms, however, suggests that a more complicated picture
exists and that the effects of repeated SORA or DORA treatment
may be unpredictable (Zhou et al., 2012). Emerging data indi-
cates that ELS and chronic stress can downregulate the activity of
the orexin system in response to chronic stress (Lutter et al., 2008;
Nocjar et al., 2012; Campbell et al., 2013). There is also a develop-
ing clinical literature indicating that depression may be associated
with decreased orexin system function (Brundin et al., 2007a,b,
2009). These studies raise potential concerns for the long-term
use of orexin antagonists in the treatment of addiction and anxi-
ety disorders, as long-term suppression of the orexin system may
precipitate depressive-like symptoms. Similarly, the emergence of
anxiety or depression under conditions of augmented orexin sys-
tem function will need to be carefully considered. Therefore, a
greater understanding of the changes to orexin receptor expres-
sion in relevant brain regions will be necessary to confidently
predict the potential outcomes of therapeutic manipulation of
orexin signaling under these conditions. Further we propose that
a thorough evaluation of chronic and subchronic orexin receptor
antagonism in preclinical animal models of anxiety and depres-
sion is necessary. Together, such approaches may be able to
identify therapeutic dosing regimens with preferential effects on
the different aspects for the orexin system that influence mood, as
well as drug- and natural-reward behaviors. Finally, the evidence
that drugs of abuse or stress can rewire inputs onto orexin neu-
rons indicates that targeting these changes within the LH might
offer an alternative strategy. This would negate the mixed down-
stream effects of SORAs and DORAs in mood, addiction and
reward by reducing aberrant orexin cell activity at the site of
dysfunction, rather than simply masking the downstream effects
using antagonists. For example, our group is currently investigat-
ing the changes in LH-orexin circuits responsible for the increased
excitatory drive observed after cocaine or ELS.
In conclusion, significant progress has been made toward an
understanding of the role of the orexin system in normal and
pathological behaviors. Unsurprisingly, given the widespread pro-
jections of the orexin system, the role for these neurons crosses
many domains including basic physiological responses to more
complex functions. Our view is that only a comprehensive dis-
section of the changes in LH-circuit function, both within the
hypothalamus and in target regions of these neurons, will reveal
appropriate therapeutic avenues to augment or suppress dysregu-
lated orexin function in neuropsychiatric and neurological disease
states.
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